Martha Rook
Chief Operating Officer chez DELCATH SYSTEMS, INC.
Profil
Martha S.
Rook is currently the Chief Operating Officer at Delcath Systems, Inc. Prior to her current position, she held the role of Secretary & Director at Alliance for Regenerative Medicine.
From 2016 to 2018, she served as the VP, Head-Gene Editing & Novel Modalities at EMD Millipore Corp.
Martha then joined Sigilon Therapeutics, Inc. in 2018 as the Chief Technical Operations Officer until 2022.
She is currently also the Chief Technical Operations Officer at Insitro, Inc. Ms. Rook holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Texas A&M University.
Postes actifs de Martha Rook
| Sociétés | Poste | Début |
|---|---|---|
| DELCATH SYSTEMS, INC. | Chief Operating Officer | 18/03/2024 |
Anciens postes connus de Martha Rook
| Sociétés | Poste | Fin |
|---|---|---|
Insitro, Inc.
 Insitro, Inc. BiotechnologyHealth Technology Insitro, Inc. engages in engages in the discovery and development of drug products. Its approach include population scale data, cell-based disease models, biology at scale, cutting-edge machine learning, and predictive insights and new medicines. The company was founded by Daphne Koller and is headquartered in Portola Valley, CA. | Chief Tech/Sci/R&D Officer | 01/03/2024 |
| SIGILON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 07/03/2022 |
EMD Millipore Corp.
 EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA. | Corporate Officer/Principal | 01/01/2018 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | - |
Formation de Martha Rook
| Massachusetts Institute of Technology | Doctorate Degree |
| Texas A&M University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DELCATH SYSTEMS, INC. | Health Technology |
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
EMD Millipore Corp.
EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA. | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Insitro, Inc.
Insitro, Inc. BiotechnologyHealth Technology Insitro, Inc. engages in engages in the discovery and development of drug products. Its approach include population scale data, cell-based disease models, biology at scale, cutting-edge machine learning, and predictive insights and new medicines. The company was founded by Daphne Koller and is headquartered in Portola Valley, CA. | Health Technology |
